Comparing that list to U.S. calculations by Bernstein Research, an analysis and investment firm, it appears the 27-nation union has a 24 percent discount on the Pfizer vaccine, paying $14.76 per dose relative to $19.50 in the United States. Some of the difference may reflect that the E.U. subsidized that vaccine’s development and the cost of shipping the European-made vaccine across the Atlantic.
The bloc will pay 45 percent less than the United States for the AstraZeneca-Oxford vaccine currently under development. But it will pay 20 percent more than the United States for the Moderna vaccine, which is expected to be approved for U.S. use on Friday. Both of those vaccines were funded partly by the U.S. government as part of Operation Warp Speed, an effort to expedite their development. The AstraZeneca-Oxford team received $1.2 billion, and Moderna got $4.1 billion.